In a one-page order filed last week, a panel of judges for the US Court of Appeals for the Federal Circuit denied Genentech’s motion for an injunction that would have blocked Amgen from selling its biosimilar bevacizumab, Mvasi, pending the outcome of an appeal.
In a one-page order filed last week, a panel of judges for the US Court of Appeals for the Federal Circuit denied Genentech’s motion for an injunction that would have blocked Amgen from selling its biosimilar bevacizumab, Mvasi, pending the outcome of an appeal.
The latest legal development stems from a dispute over the notice of commercial marketing for the biosimilar. In September 2017, the FDA approved the biosimilar, and in October of the same year, Amgen sent Genentech, maker of the reference bevacizumab, Avastin, its notice of commercial marketing. The letter indicated that Amgen would not launch the drug earlier than 180 days from the letter’s date.
After giving Genentech its notice, Amgen filed a number of supplements to its Biologics License Application (BLA) with the FDA, including changes to the labeling for the biosimilar.
According to Genentech, because Amgen had filed these supplements, the Mvasi product authorized by the FDA after the supplements were approved was different from the product approved in 2017. Genentech sought an order prohibiting Amgen from marketing the biosimilar until 180 days after filing a new notice of commercial marketing.
The court disagreed, saying that the Mvasi product that was subject to the FDA’s original approval is the same as the product for which supplements to the BLA were also approved. The court found that Genentech could not succeed on the merits, and “that finding alone necessitates denial of Genentech’s motion.”
Genentech then sought an injunction on sales of Mvasi pending an appeal of that decision.
According to the court’s order issued on Friday, determining whether to grant an injunction takes into account 4 factors: whether the party moving for an injunction has a strong likelihood of succeeding on the merits, whether that party will be irreparably injured without an injunction being granted, whether an injunction would injure other parties, and where the public interest lies.
“Without prejudicing the ultimate disposition of this case, we conclude that Genentech has not established that an injunction pending appeal is warranted here under these factors,” the court’s order read.
Earlier this month, the court also denied Genentech’s motion for an injunction that would have barred sales of another Amgen biosimilar, Kanjinti (a trastuzumab biosimilar referencing Genentech’s Herceptin) pending the resolution of an appeal in a separate case.
Mvasi and Kanjinti were launched simultaneously last month, and have enjoyed early support; provider group OneOncology indicated that it has begun treating patients with the agents, and UnitedHealthcare has announced that it will make both of the biosimilars preferred oncology agents on its formulary as of October 2019.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.